PubRank

Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84)

Clinical Trial ID NCT04815720

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04815720

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 14.71
2 The B7 family revisited. Annu Rev Immunol 2005 13.51
3 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005 12.88
4 PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014 10.39
5 The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 9.39
6 Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008 7.80
7 PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010 6.20
8 CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005 6.18
9 The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010 5.99
10 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004 5.59
11 Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999 5.07
12 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005 4.94
13 SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004 4.58
14 Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007 4.41
15 B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003 3.96
16 PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 2001 3.32
17 PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004 2.77
18 PD-1 signaling in primary T cells. Immunol Rev 2009 2.66
19 Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010 2.24
20 Immune regulation of cancer. J Clin Oncol 2010 1.99
21 Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010 1.98
22 Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014 1.92
23 Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004 1.70
24 Structural basis of semaphorin-plexin signalling. Nature 2010 1.58
25 Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov 2015 1.28
26 Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 2010 1.13
27 Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res 2015 1.02
28 Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 2007 0.99
29 iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017 0.91
30 Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody. Mol Cancer Ther 2015 0.88
31 Generation and preclinical characterization of an antibody specific for SEMA4D. MAbs 2015 0.80
32 Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer. Asian Pac J Cancer Prev 2013 0.80
33 Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. J Immunol 2016 0.80
34 Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial. Neurol Neuroimmunol Neuroinflamm 2017 0.75
35 Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget 2017 0.75
Next 100